Creative Planning Sells 149 Shares of Eli Lilly and Company (NYSE:LLY)

Creative Planning trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.1% during the third quarter, Holdings Channel.com reports. The firm owned 228,526 shares of the company’s stock after selling 149 shares during the period. Creative Planning’s holdings in Eli Lilly and Company were worth $202,373,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in LLY. Capital Planning LLC bought a new stake in shares of Eli Lilly and Company during the first quarter valued at about $262,000. CHURCHILL MANAGEMENT Corp bought a new stake in shares of Eli Lilly and Company in the first quarter worth about $6,916,000. M&G Plc bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $8,896,000. BTC Capital Management Inc. purchased a new position in Eli Lilly and Company during the 1st quarter valued at $1,432,000. Finally, High Net Worth Advisory Group LLC raised its stake in Eli Lilly and Company by 1.4% in the first quarter. High Net Worth Advisory Group LLC now owns 4,919 shares of the company’s stock worth $3,827,000 after buying an additional 67 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $917.86 on Friday. The firm has a fifty day simple moving average of $921.21 and a two-hundred day simple moving average of $857.37. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The stock has a market capitalization of $872.34 billion, a P/E ratio of 135.18, a PEG ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. On average, analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on LLY. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,025.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Citigroup assumed coverage on shares of Eli Lilly and Company in a research note on Friday, September 13th. They set a “buy” rating and a $1,060.00 target price for the company. BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $986.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.